Hierarchical interactions model for predicting Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD) conversion

Han Li1, Yashu Liu2, Pinghua Gong1

  • 1State Key Laboratory on Intelligent Technology and Systems, Tsinghua National Laboratory for Information Science and Technology (TNList), Department of Automation, Tsinghua University, Beijing, P.R. China.

Plos One
|January 14, 2014
PubMed

Insights

Predicting dementia conversion in Mild Cognitive Impairment (MCI) is crucial for early Alzheimer's disease (AD) treatment. This study introduces a novel method using biosignature interactions, significantly improving prediction accuracy over existing approaches.

Area of Science:

  • Neuroscience
  • Medical Imaging
  • Biostatistics

Background:

  • Accurate prediction of Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) conversion is vital for early intervention.
  • Current prediction systems using individual biosignatures are insufficient for reliable forecasting.

Purpose of the Study:

  • To develop an improved prediction model for MCI to AD conversion by incorporating pairwise biosignature interactions.
  • To identify significant biosignatures and their interactions that predict conversion to dementia.

Main Methods:

  • Utilized hierarchical constraints and sparsity regularization for feature selection from high-dimensional biosignature data.
  • Developed classification models based on significant biosignatures and their interactions.
  • Analyzed biosignature interaction effects using stable expectation scores.

Main Results:

  • The proposed method demonstrated superior classification performance compared to state-of-the-art techniques.
  • Identified several significant pairwise biosignature interactions that are predictive of MCI to AD conversion.
  • The study utilized MRI data from 293 MCI subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

Conclusions:

  • Incorporating biosignature interactions enhances the accuracy of MCI to AD conversion prediction.
  • The findings offer new insights into the complex interplay of biosignatures in AD progression.
  • This approach holds promise for improving early diagnosis and monitoring of Alzheimer's disease.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K